IMV Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 bal. 2023 @ 22:58):

Stats
Dzisiejszy wolumen	44 894.00
Średni wolumen	152 414
Kapitalizacja rynkowa	9.63M
EPS	$0 ( 2024-03-14 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.181
ATR14	$0.0680 (56.62%)

Wolumen Korelacja

Długi: 0.02 (neutral)

Krótki: 0.97 (very strong)

Signal:(34.598) Expect same movement, but be aware

IMV Inc Korelacja

10 Najbardziej pozytywne korelacje
NAKD	0.952
MDXH	0.943
GSMG	0.941
SIRI	0.94
AHPI	0.939
TENX	0.938
TSHA	0.937
CSSE	0.936
BCBP	0.933
SINT	0.933

10 Najbardziej negatywne korelacje
KIN	-0.957
ATCX	-0.957
ALGM	-0.955
SRRA	-0.948
NCAC	-0.945
OBT	-0.942
INTA	-0.939
GXII	-0.939
ITI	-0.938
DHCAU	-0.937

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

IMV Inc Korelacja - Waluta/Towar

0.36
( neutral )

0.45
( neutral )

0.58
( weak )

0.52
( weak )

0.38
( neutral )

-0.44
( neutral )

IMV Inc Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-4.61

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-4.61

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.0737

FY	2020
Przychody:	$3 000.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.0578

Financial Reports:

No articles found.

IMV Inc

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.